David W. Kimberlin, M.D.
Associate Professor of Pediatrics
Division of Pediatric Infectious
The University of Alabama at
1600 Seventh Avenue South, CHB 303
Birmingham, AL 35233
Since joining the faculty at The
University of Alabama at Birmingham in 1996, Dr. David Kimberlin has overseen
all pediatric studies conducted by the National Institute of Allergy and
Infectious Diseases’ Collaborative Antiviral Study Group, and serves as Co-PI on
the CASG contract. The CASG is an NIH-sponsored, multicenter, international
organization of academic medical centers that conducts antiviral therapeutic
trials for orphan diseases which do not receive the attention and research
investments of pharmaceutical companies. It consists of approximately 35
centers in the United States, Canada, the United Kingdom, and Sweden. The
University of Alabama at Birmingham has served as the CASG Central Unit since
its inception in 1972. Since 1996, Dr. Kimberlin has directly overseen and
managed international CASG investigations of the treatment of neonatal herpes
disease, congenital cytomegalovirus disease, neonatal and infantile enteroviral
disease, and juvenile-onset recurrent respiratory papillomatosis.
also serves as the Medical Director of the University of Alabama at Birmingham
Pediatric Clinical Trials Office, and he is the Associate Director of the
University of Alabama at Birmingham General Clinical Research Center (GCRC).